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Abstract
Hepatitis C virus (HCV) infection is one of the major causes of advanced liver disease and 
hepatocellular carcinoma (HCC) worldwide. While the knowledge about the molecular virology of 
HCV infection has markedly advanced, the molecular mechanisms of disease progression leading 
to fibrosis, cirrhosis and HCC are still unclear. Accumulating experimental and clinical studies 
indicate that HCV may drive hepatocarcinogenesis directly via its proteins or transcripts, and/or 
indirectly through induction of chronic liver inflammation. Despite the possibility to eradicate 
HCV infection through direct-acting antiviral treatment, the risk of HCC persists although specific 
biomarkers to estimate this risk are still missing. Thus, a better understanding of HCV-induced 
HCC and more physiological liver disease models are required to prevent cancer development.
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Introduction
Hepatitis C virus (HCV) is single-strand RNA virus from the Flaviviridae family targeting 
hepatocytes. Chronic HCV infection induces immune dysfunctions such as impaired T-cell 
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functions and inefficient antibody responses, metabolic disorders such as hepatic steatosis, 
iron accumulation, and insulin resistance often associated with type 2 diabetes. More 
importantly, HCV is one of the major etiologies of chronic hepatitis and progressive liver 
fibrosis that lead to development of lethal complications, i.e., cirrhosis and hepatocellular 
carcinoma (HCC), the second leading cause of cancer mortality worldwide and the only and 
most rapidly increasing cancer death in the U.S. [1,2]. Chronic HCV infection is highly 
prevalent globally, including developed countries [3]. In the U.S., more than 1 million 
individuals, representing the “baby boomer” population, are estimated to develop HCV-
related liver cirrhosis and/or HCC by 2020. Recently developed direct-acting antivirals 
(DAAs) for HCV effectively cure HCV infection, i.e., they enable to achieve sustained 
virologic response (SVR), but the high costs will limit their wide-spread use [4]. Of note, 
HCC risk remains high for decades even after SVR, and HCV-related HCC is predicted to 
increase until 2030 despite improved viral cure by DAAs [5,6].
HCV does not integrate its genetic material into the host genome, and therefore requires 
continuous replication to maintain chronic infection. Many host factors, playing essential 
roles in the HCV life cycle and immune evasion, have been identified as candidate targets 
for antiviral interventions (reviewed in [7]). However, disease pathogenesis that ultimately 
causes HCC is still unclear. Experimental studies to date have suggested models of viral 
carcinogenesis unique to HCV [8]. Increasing evidence shows that HCV transmits signals 
and modulates hepatocyte gene expression following engagement with cellular receptors 
[9,10]. Moreover, viral proteins have been involved in disrupting signal transduction 
pathways that affect cell survival, proliferation, and transformation [8]. This suggests that 
virus-host interactions and signaling during viral infection contribute to cellular 
transformation and development of HCC directly via HCV proteins or RNA, and/or 
indirectly through induction of chronic inflammation. Additionally, the genetic background 
of the host may play a role in HCC pathogenesis. Genetic analyses in HCV-infected patients 
have unraveled specific mutation or polymorphisms in MICA/HCP5, LEPR and IFNL3 loci 
that are associated with the development of HCC [11–16], indicating that genetic variation 
may contribute to individual susceptibility for HCV-driven HCC.
Of note, the persisting risk of HCC development even after viral cure suggests that HCV 
leaves molecular imprinting in the host genome that keeps driving carcinogenesis. 
Management of post-SVR HCC will be increasingly relevant as more patients achieve SVR 
by the DAA treatment in clinic. Here, we review several examples of mechanisms that may 
contribute to HCV-induced HCC and discuss the clinical challenges to prevent HCC 
development in at-risk patients in the era of DAA-based anti-HCV therapies.
Viral factors directly driving hepatocarcinogenesis
The strong and reproducible association of HCV genotype 3 with development of steatosis 
and HCC, genotype 1b with more frequent progression to HCC, and HCV core gene variants 
with post-SVR HCC suggests that specific viral factors influence or determine progression 
of liver disease [17–19]. The viral genome encodes for three structural (core, E1, E2) and 
seven non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B). Several in 
vivo studies in transgenic mouse models reported direct induction of liver disease by the 
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expression of viral proteins (reviewed in [20]). Although none of these models could 
faithfully recapitulate the full features of human disease, some of the phenotypes were 
consistent with epidemiological data from HCV-infected patients. Interestingly, these studies 
highlighted that HCV RNA and proteins can perturb hepatocellular homeostasis by driving 
several major cancer hallmarks (Figure 1).
First, metabolic reprogramming including disturbance of lipid metabolism and 
mitochondrial dysfunction were shown to play an important role in HCV-driven HCC 
(Figure 1). Indeed, chronic HCV infection enhances mitochondrial liver injury together with 
oxidative stress in human as well as experimental models [21]. Several studies highlight a 
role of the HCV core protein in steatosis and HCC nodule development as well as in insulin 
resistance, which is accompanied with intrahepatic lipid accumulation [20,22]. The 
alteration of lipid metabolism is induced by an HCV core-mediated impairment of lipid β-
oxidation, which is associated with a reduced activity of the mitochondrial electron transport 
chain [20]. Recently, HCV core protein was also shown to contribute to mitochondrial 
damage by impairing mitophagy [23]. The resulting oxidative stress is regarded as a key 
trigger of HCC initiation and development (Figure 1). Imbalance of the oxidant/antioxidant 
state in the liver was shown to induce HCC in HCV core transgenic mice in the absence of 
inflammation [24]. Moreover, generation of reactive oxygen species (ROS) in the course of 
HCV infection was associated with genomic instability, a hallmark of cancer cells [20]. 
Indeed, accumulation of genetic mutations as well as chromosomal alterations crucially 
drive the development of HCC in patients [25]. By inducing a β-Catenin-dependent 
upregulation of c-Myc via NS5A, HCV was shown to perturb ROS production in association 
with enhanced DNA damage and aberrant cell-cycle arrest (Figure 1) [26]. In addition, 
increased telomerase (TERT) activity, a characteristic of transforming or transformation-
prone cells, was observed in HCV core-transfected primary human hepatocytes that acquired 
an immortalized phenotype [27]. In line with this observation, somatic mutations in the 
TERT promoter that enhance TERT expression were shown to be among the earliest and 
most prevalent neoplastic event in HCC associated with all major etiologies including HCV 
[28].
Another major hallmark of cancer that is directly affected by HCV is evasion from cell death 
and senescence (Figure 1). Although HCV proteins were reported to have both pro-apoptotic 
and anti-apoptotic properties [8], HCV is likely involved in evasion from apoptosis in vivo. 
A number of studies indicate that Fas-mediated apoptosis is directly inhibited by different 
HCV proteins [20,29–31]. Given that the Fas system accounts for T cell-mediated 
cytotoxicity, suppression of cell death is not only a mechanism of sustained cell proliferation 
but also one strategy that enables HCV to escape immune surveillance by T cells and thus to 
establish persistent infection [32].
Finally, recent evidence indicates that viral proteins impact on epithelial mesenchymal 
transition (EMT) pathway, which promotes fibrogenesis, tumor development and metastases 
(Figure 1). HCV NS5A was shown to activate Twist2, a transcriptional regulator of EMT, 
and to cooperate with Ras oncogene to enhance tumor cell invasiveness in xenograft mouse 
models [33]. Furthermore, expression of HCV core in transgenic mice enhances intrahepatic 
TGF-β signaling, a key regulator of EMT driving the activation of human stellate cells 
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(HSCs) [34]. Further studies showed that induction of EMT by HCV core is mediated by at 
least two mechanisms: i) the inhibition of E-cadherin expression by a complex comprising 
HCV core, Snail and the histone deacetylases HDAC1/HDAC2 [35]; ii) the HCV core-
induced epigenetic silencing of SFRP1 via DNA methylation and histone modifications that 
in turn activates Wnt/β-catenin signaling [36]. Yet the clinical relevance of these recent 
findings remains to be determined.
HCV-induced inflammatory responses indirectly driving 
hepatocarcinogenesis
HCV infection can induce chronic hepatic inflammation with varying activity, which causes 
progressive liver fibrogenesis and leads to development of cirrhosis (Figure 1). Clinically, 
the majority of HCV-related HCC tumors develop in livers with cirrhosis established after 
decades of chronic inflammation, underscoring the key role of virus-induced inflammatory 
responses, besides the viral materials themselves, in HCC pathogenesis. Several 
inflammatory pathways have been implicated in HCC. First, the sensing of HCV infection 
by pathogen recognition receptors of the innate immune system activates the NF-κB 
signaling and downstream proinflammatory chemokines and cytokines including type III 
interferon (IFN), which is associated with HCC development (Figure 1) [37–39]. Ectopic 
lymphoid structure aggregated near the portal tract was reported as a niche of HCC initiation 
associated with striking NF-κB activation in a subset of HCV-infected human livers [40]. 
Approximately in 70 % of chronic hepatitis C (CHC) patients the immune response fails to 
eradicate the virus due to impaired T cell and antibody responses, and little antiviral efficacy 
of IFN-stimulated genes (ISGs) [41]. The adaptive immune response mediated by cytotoxic 
T cells has been suggested to contribute to liver injury by triggering repeated cycles of 
hepatocyte death and regeneration/proliferation. The inflammatory response also exacerbates 
oxidative stress in the liver (Figure 1). Cytokines, ROS and apoptotic signals contribute to 
HSC activation, which triggers aberrant deposition of extracellular matrix proteins and 
progressive fibrosis (Figure 1). As such, the functional liver parenchyma is progressively 
replaced by non-functional fibrotic tissue. Overall, this pattern of chronic inflammation, 
unresolved wound healing response and increased hepatocellular proliferation in CHC is 
thought to generate an environment highly permissive for hepatocarcinogenesis.
Despite the growing knowledge, many open questions remain unanswered. The molecular 
bases of the interplay between the innate and adaptive immune responses in the course of 
CHC and their relevance for HCC development are still largely unclear [41]. IFN pathway 
activation is one of the key components of the host responses to HCV, although cell types 
secreting IFN as well as types of secreted IFN stimulating specific subset of ISGs are still 
elusive. This is partly because of the lack of a robust immunocompetent in vivo HCV 
infection model that mirrors the cell circuits of HCC development as well as the crosstalk 
between parenchymal and non-parenchymal cell types driving disease progression under 
physiological condition as in human [20]. Transgenic mouse models coupled with 
epidemiological data in patients have provided important insights into mechanistic 
investigation. This approach was successful in unraveling a pathway of hepatocarcinogenesis 
driven by the pro-inflammatory cytokine lymphotoxin (LT) α and β [42]. By using 
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transgenic mice for either LTs expression or NF-κB signaling components, Haybeack et al. 
discovered that LTs overexpression induces chronic hepatitis and HCC by altering NF-κB 
signaling in both hepatocytes and lymphocytes. These observations were corroborated by the 
enhanced LT expression in clinical liver specimens from virus-induced chronic hepatitis and 
HCC as compared to healthy liver [42]. More recently, HCV NS5B was shown to promote 
pro-inflammatory LTβ signaling in liver cells [43]. Likewise, two recent studies casted new 
light on novel mechanisms of HSC activation and liver fibrogenesis in CHC. The first 
involves the acetylation of HMGB1 by extracellular osteopontin (OPN), a stress sensor 
protein that is enhanced in liver disease and elevated in serum of patients who are at risk of 
HCC development [44]. Acetylated HMGB1 interacts with HDAC1/HDAC2 to promote 
collagen-I expression by HSCs and increase its histological deposition [45]. The second 
mechanism relies on the upregulation of the Gas6/Axl pathway in HSC leading to activation 
of these cells and liver fibrogenesis upon carbon tetrachloride-induced injury in mice [46]. 
Importantly, the clinical relevance of both mechanisms was evidenced by the correlation 
between the severity of liver injury and increased expression of OPN/HMGB1 or Gas6/Axl, 
respectively, in HCV-infected patients [45,46]. However, additional clinical cohort studies 
may be required to corroborate the involvement of these processes in HCV pathogenesis.
Treatment of HCV infection and prevention of HCC
Rapidly evolving DAA-based anti-HCV therapies now enable more than 90% of SVR rate 
with all-oral regimens even in the cases hard to cure before [47]. In patients previously 
treated with older, IFN-based regimens, SVR was significantly associated with reduced but 
not eliminated future risk of HCC development over a decade [48]. In the retrospective 
studies, several clinical characteristics such as more advanced liver fibrosis, older age, and 
male sex among others have been suggested as predisposing factors for post-SVR HCC 
(Table 1). However, estimation of HCC risk in patients newly achieving an SVR is still 
infeasible and the mechanisms of carcinogenesis are totally unknown. Given the annual 
incidence of post-SVR HCC, which is likely below the threshold that rationalizes regular 
HCC surveillance, HCC risk biomarkers or indices will play a critical role to perform cost-
effective and practically feasible HCC surveillance by triaging the patients according to the 
predicted HCC risk [21]. Also, such biomarkers may provide clues to targets of HCC 
chemopreventive interventions. It is still unanswered question whether HCC risk after DAA-
based or other types of anti-HCV therapies such as viral entry inhibition [49] is comparable 
to that of IFN-based therapies. Modulation of cellular signaling pathways such as IFN, EGF, 
mTOR, and retinoid X receptor-α pathways and drugs for metabolic disorder, some of 
which have been already clinically evaluated, may serve as alternative options of HCC 
chemoprevention for broader etiologies, including post-SVR HCC [50–56]. Experimental 
systems that allow mechanistic assessments of the carcinogenic drivers will be critical in 
identifying and developing rational molecular-targeted HCC chemoprevention therapies.
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Highlights
• The molecular mechanisms of HCV-driven HCC are still elusive.
• HCV perturbs hepatocellular homeostasis by driving several major 
cancer hallmarks.
• HCV-induced inflammatory responses indirectly drive 
hepatocarcinogenesis.
• Biomarkers to predict HCC risk in patients after HCV cure are missing.
• HCV may leave a cancer-prone molecular imprinting in the host 
genome.
• Novel experimental systems are needed to assess HCC drivers 
mechanistically.
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Figure 1. HCV RNA and proteins perturb hepatocellular homeostasis by driving major cancer 
hallmarks
The diagram (adapted from [8]) shows the HCV-host interactions and signaling upon viral 
infection that contribute to cellular transformation and development of HCC. The red arrows 
indicate HCV RNA and proteins exerting a direct effect on a specific hallmark. Black arrows 
link specific hallmarks to examples of mechanisms of HCV-driven HCC, which were 
observed in both clinical and in vivo experimental models. Regarding the tumor promoting 
inflammation hallmark (in orange in the diagram), this is activated by the pathogen 
recognition receptors that sense HCV infection. Dotted lines indicate examples of 
inflammation-driven carcinogenesis. sRNA, small RNA.
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Table 1
Clinical risk factors for post-SVR HCC development
Type of anti- 
HCV therapy No. SVR patients Follow-up period (y) Risk factors for HCC development References
IFN-based 1197 5.9 Age ≥ 50 y, male, F3/4 fibrosis [57]
IFN-based 1056 4.7 Age ≥ 60 y, AST ≥ 100 U/L, platelets < 150 ×109/L [58]
IFN-based 871 3.4 F3/4 fibrosis, age ≥ 60 y, post-SVR AFP ≥ 20 ng/mL, 
platelets < 150 ×109/L
[59]
IFN-based 1751 8.1 Diabetes, male, alcohol, age (every 10 y) [60]
IFN-based 1425 3.3 Post-SVR AFP ≥ 5 ng/mL, Age ≥ 65 y [61]
IFN-based 562 4.8 F2/3/4 fibrosis, age ≥ 50 y, ethanol ≥ 30 g/d, pre-SVR 
AFP ≥ 8 ng/mL
[62]
IFN-based 642 4.4 GGT ≥ 75 U/L, age ≥ 65 y, F2/3 fibrosis [63]
IFN-based 522 7.2 Diabetes, FIB-4 index [64]
IFN-based 801 5.0 Age ≥ 60 y, post-SVR AFP ≥ 20 ng/mL platelets < 150 
×109/L, F3/4 fibrosis
[15]
IFN-based 83 HCC among 2152 
SVR
6.7 No surveillance (for risk of advanced HCC) [65]
IFN-based 10817 2.8 cirrhosis, age ≥ 65 y, diabetes, HCV genotype 3 [66]
IFN-based 1351 n.a. Pre/post-SVR AFP ≥ 15 ng/mL, pre/post-SVR APRI ≥ 
0.7
[67]
IFN-based 399 7.8 Cirrhosis, diabetes [68]
IFN-based 24 SVR HCC cases vs. 
96 matched controls
n.a. Compensated cirrhosis, post-SVR albumin ≤ 36 g/L [69]
IFN-based 376 7.6 Advanced fibrosis/cirrhosis, diabetes, LSM > 12 kPa [70]
IFN-based 1094 4.2 Age ≥ 60 y, male, F3/4 fibrosis, post-SVR AFP ≥ 10 
ng/mL
[71]
IFN-based 598 5.1 Pre/post-SVR APRI ≥ 1.0 [72]
SVR: sustained virologic response, HCC: hepatocellular carcinoma, HCV: hepatitis C virus, y: years, IFN: interferon, AFP: alpha-fetoprotein, 
GGT: gamma-glutamyl transpeptidase, FIB-4: fibrosis-4, LSM: liver stiffness measurement, APRI: aspartate aminotransferase-to-platelet ratio 
index, n.a.: not available.
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